An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding provided by University of Lausanne”.
The original version of this article has been updated.
. 2023 Mar 21;14:1183107. doi: 10.3389/fimmu.2023.1183107
Erratum: The efficacy of cancer immunotherapies is compromised by Helicobacter pylori infection
Frontiers Production Office1,*
1
Frontiers Media SA, Lausanne, Switzerland
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
✉
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
Received 2023 Mar 9; Accepted 2023 Mar 9; Collection date 2023.
Keywords: Helicobacter pylori; cancer; immunotherapy, personalized medicine; gut microbiota; immune checkpoint inhibitors
Copyright © 2023 Frontiers Production Office
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
PMCID: PMC10072902 PMID: 37026018
This corrects the article "The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection" in volume 13, 899161.